Ionotropic glutamate receptors (iGluRs) are tetrameric ligand gated ion channels that mediate excitatory synaptic transmission in the central nervous system^[@R7]^. They have been classified into large families of AMPA, kainate, and NMDA receptors that have distinct functional, pharmacological, and structural properties^[@R8],[@R9]^. Understanding the structural basis of glutamate receptor function is vital to understanding their roles in learning and memory, and by extension their roles in neuropathology. Crystallographic and cryo-EM studies of AMPA and kainate receptors^[@R3]--[@R6],[@R10]--[@R15]^ revealed large conformational changes between states, including dramatic changes in the arrangement of the ligand binding domain (LBD) in the desensitized state in both receptor types. While near-atomic resolution structures have been reported for the AMPA receptor GluA2 subtype in apo^[@R3]^, antagonist-bound^[@R6],[@R14]^, and pre-activated states^[@R3],[@R10],[@R14]^, a high-resolution structure of the desensitized state of any glutamate receptor subtype has remained elusive. Thus, the central question of how a closed ion channel can be accommodated in both resting and desensitized states in the context of dramatically different LBD layer structures has remained unanswered. The structure we present here of the desensitized state of GluK2 reveals unexpected aspects of how conformational changes are coupled to symmetry mismatches across the length of the receptor and thereby allows delineation of a complete model for the glutamate receptor gating cycle.

In our experiments we used GluK2~EM~, a construct that binds GluK1 selective antagonists with nanomolar affinity, and trapped the desensitized state using (2S,4R)-4-methylglutamate, a high affinity agonist that promotes profound desensitization^[@R16],[@R17]^. The GluK2~EM~ desensitized state structure at 3.8 Å resolution ([Extended Data Fig. 1](#F5){ref-type="fig"}) reveals a 2-fold symmetric amino terminal domain (ATD) layer ([Figs. 1a, 1b](#F1){ref-type="fig"}) with an intact ATD tetramer interface ([Fig. 1c](#F1){ref-type="fig"}), and a reorganized LBD layer resembling a pinwheel ([Fig. 1d](#F1){ref-type="fig"}). In the transmembrane domain (TMD) layer, all three membrane-spanning helices, and the S1-M1 and M3-S2 linkers were resolved ([Extended Data Figs. 2a, 2b](#F6){ref-type="fig"}), and the four subunits within the ion channel display an approximately 4-fold symmetric relationship ([Fig. 1e](#F1){ref-type="fig"}). Density for complex glycans at positions Asn244, Asn347 and Asn399 is evident ([Extended Data Fig. 2c](#F6){ref-type="fig"}), while the M2 pore helices were not resolved and the ATD-LBD linker for the B and D subunits, and the C-terminal domain appear only at low density map contours. High sequence identity (\>85%) between the M3 helices of AMPA and kainate receptors suggests that the general architecture of the central pore of the GluK2 channel will be relevant to other receptor subtypes from both families. In order to validate the use of 2-fold computational symmetry in the reconstruction, the data was reprocessed entirely without symmetry ([Extended Data Fig. 3](#F7){ref-type="fig"}). The resulting reconstruction yielded a structure with the same architecture and domain placement as when 2-fold symmetry was applied, but at slightly lowered resolution. This result thereby supports the use of 2-fold symmetry in processing the data, and shows the presence of 2-fold symmetry in the desensitized state.

The competitive antagonist LY466195 has nanomolar affinity for GluK2~EM~ ([Extended Data Fig. 4](#F8){ref-type="fig"}). We used this ligand to trap and determine the structure of the antagonist-bound resting state to \~12 Å and fit crystal structures of GluK2 ATD dimers and GluK2~EM~ LY466195-bound LBD dimers to the cryo-EM map ([Extended Data Fig. 5](#F9){ref-type="fig"}). The GluK2~EM~ resting state structure is consistent with that observed previously using cryo-electron tomography^[@R5]^, and its structural profile matches that of the cryo-EM and crystal structures of the antagonist-bound resting state of GluA2^[@R4],[@R6]^. The lower resolution of the antagonist-bound resting state likely reflects greater conformational heterogeneity compared to the desensitized state, potentially arising from variability in the relative orientations of the ATD and LBD layers.

Using the cryo-EM density maps, we built a de novo atomic model of full-length desensitized state GluK2~EM~, and a molecular model of resting state GluK2 from crystal structures of ATD (PDB ID: 3H6G) and LBD (PDB ID: 5CMK) dimers. In the description below, we use "A", "B", "C" and "D" to refer to the four subunits of the tetrameric receptor, and "AC" and "BD" rather than the terms "proximal" and "distal" chains to clarify discussion of connectivity between the three (ATD, LDB and TM) layers of the receptor. Comparison of the resting and desensitized state models show that although the ATD tetrameric layers are essentially similar in both states, the LBDs splay outwards upon desensitization, tugging on the ATD assembly via the ATD-LBD linkers and pulling it downwards compared to the resting state, creating a substantial, 1,250 Å^2^ buried surface area interface between the ATD AC subunits and their underlying LBDs ([Extended Data Fig. 6](#F10){ref-type="fig"}). This interface, which likely explains how the ATD contributes to stabilization of the desensitized state^[@R18]^, is mediated by van der Waals interactions combined with salt bridges and hydrogen bonds formed between the side chains of Lys191 and Asp476, Glu219 and Arg400, and Tyr220 and Asp480 of the ATD and LBD, respectively. Notably, linkers connecting the ATD and LBD layers adopt a helical structure that packs against the upper lobe of the LBD, a feature not seen in prior AMPA and kainate receptor structures. In the GluK2~EM~ resting state the ATD and LBD layers do not interact and are separated by \~15 Å, similar to the GluA2 antagonist-bound resting state solved by cryo-EM^[@R4]^, which shows a separation of \~12 Å. This is strikingly different from GluA2 resting state crystal structures, which have 4-6 residue deletions in the ATD-LBD linkers (PDB IDs: 3KG2, 4U2P and 4U4G), and closely apposed ATD and LBD layers with a buried surface area of 400--530 Å^2^ per subunit, but without the helical structure found in the ATD-LBD linker of the GluK2 desensitized state^[@R3],[@R6],[@R14]^. Comparison of the GluK2~EM~ resting state with the extended structure of the pre-activated GluA2 complex with con-ikot-ikot toxin^[@R10]^, for which the ATD-LBD linkers contain only 2 deletions, suggests that wild type GluA2 ATD-LBD linkers *can* extend to sufficient length such that the ATD and LBD are not in contact in both receptor subtypes, as also suggested by computational experiments^[@R19]^. We conclude that the apparent discrepancy among GluA2 and GluK2 resting states solved by cryo-EM where no buried surface is observed for the ATD-LBD interface, and the subset of GluA2 resting states solved by crystallography where these domains are in contact, is attributable to the dynamic structure of these domains^[@R19]^, combined with the effects of crystal packing and truncations in the ATD-LBD linkers in the GluA2 crystallization constructs. However, we note that while overall the GluA2 and GluK2 resting state structures are remarkably similar, they are both strikingly different from the compact resting state structure recently reported for GluA2/GluA3 heteromers^[@R11]^.

The organization of the LBD layer in the desensitized state is most strikingly characterized by \~125° rotations of AC subunit LBDs and displays \~4-fold in plane rotational symmetry ([Fig. 1d](#F1){ref-type="fig"}) in contrast to the 2-fold symmetry of the ATD layer ([Fig. 1c](#F1){ref-type="fig"}). Helices E and G from individual subunits abut onto the same two helices on neighboring LBDs ([Figs. 2a--2c](#F2){ref-type="fig"}). Instead of the arrangement that would be expected if the LBD layer showed perfect 4-fold symmetry ([Fig. 2d](#F2){ref-type="fig"}), we observe instead a circular arrangement that proceeds around the interior surface of the LBD layer with the E/G helices in an alternating, staggered pattern that we name the "desensitization ring" ([Fig. 2e](#F2){ref-type="fig"}). This ring-like structure effectively creates a local 2-fold organization in the context of the global pseudo 4-fold arrangement of the overall LBD-layer. As a result, there are asymmetric contacts at AB and AD subunit interfaces that have buried surfaces of 860 Å^2^ and 447 Å^2^, respectively. Hydrogen bonds are formed between the Lys645 main chain and the side chain of Thr670, and salt bridges between the side chains of Asp672 and Lys667, and Asp672 and Lys673 in the AB subunit interface, with hydrogen bonds connecting the side chains of Ser639 and Arg681, and Tyr671 and Ser680 in the AD subunit interface. A structural consequence of the staggered E/G helix organization is that the BD subunit LBDs have a different pitch than the AC domains, with the AC subunits tilting away from the central receptor axis by \~10° more than their counterparts ([Fig. 2e](#F2){ref-type="fig"}). It is this tilting which permits the E/G helices of the AC subunits to occupy the more elevated position in the staggered ring. Taken together, we observe that the LBD tetramer thus displays elements of both 4-fold and 2-fold symmetry. The apparent 4-fold symmetry manifests when considering the in-plane rotation of the LBD domains as viewed down the central axis of the receptor. The 2-fold symmetry, which ultimately defines the symmetry of the LBD layer, is apparent when accounting for the staggered helix E/G arrangement in the "desensitization ring". This staggered ring structure demands a symmetry mismatch in AC versus BD subunit LBDs, which is accomplished by the mismatched pitches in the domains.

To test if the desensitization ring contributes to the stability of the desensitized state, we used the structure to guide placement of arginine mutations at positions that would be expected to disrupt inter-subunit interactions. We chose S669R and D672R, both on helix G of the LBD, and measured their effects on the extent and rates of onset and recovery from desensitization. The extent of desensitization did not decrease ([Fig. 2g](#F2){ref-type="fig"}), but both mutations speed recovery from desensitization ([Figs. 2h, 2i](#F2){ref-type="fig"}, [Extended Data Fig. 7](#F11){ref-type="fig"}, and [Extended Data Table 1](#T1){ref-type="table"}). Additionally, the nature and magnitude of this effect is consistent with previous reports identifying A676T and S679R mutations^[@R20],[@R21]^, both of which, like the residues chosen in our functional experiments, reside on helix G ([Extended Data Fig. 7](#F11){ref-type="fig"}). These results substantiate the hypothesis that the desensitization ring contributes to the stability of the state. Moreover, because these mutations do not reduce the extent of desensitization, other structural features *must* contribute to the deep energy well of the desensitized state. The ion channel region of the structure appears to be such a candidate, with its high relative structural stability in the cryo-EM density map ([Extended Data Fig. 1e](#F5){ref-type="fig"}).

The desensitized state structure also reveals disruption of allosteric ion binding sites that facilitate receptor activation^[@R22]--[@R24]^ and suggests an attractive mechanism for the recovery to the resting state from the desensitized state. Superposition of an open cleft GluK2~EM~ LBD crystal structure (PDB ID: 5CMK) via domain 1 coordinates on the closed cleft LBDs within the desensitized structure reveals severe steric clashes, which implies that the desensitization ring must start to reorganize before the LBD can fully open. This observation that the desensitization ring must begin reorganizing *before* the LBD can adopt an open cleft conformation immediately provides a structural explanation for the electrophysiological observation of channel activity during recovery from desensitization^[@R25]^.

Inspection of the TM region in the desensitized state shows that the overall channel architecture is remarkably similar to that reported for AMPA receptor structures in the apo and antagonist-bound resting states ([Figs. 3a--3d](#F3){ref-type="fig"}), with residues M633, T629 and T621 forming constrictions in the pore that prevent ion permeation. High sequence similarity in the transmembrane regions of AMPA and kainate receptors, with the GluK2 desensitized structure reported here complementing previously reported GluA2 structures in apo, resting, and pre-activated states, makes possible a comparative analysis of closed channel glutamate receptor structures. This comparison makes clear that while the ion channel in these different states adopts a similar overall profile ([Fig. 3e](#F3){ref-type="fig"}), there is a substantial difference at the entrance to the pore in the desensitized and agonist-bound pre-activated states, with a collapse to the resting state structure in the desensitized state compared to the expanded conformation observed in the pre-activated state^[@R10]^. That all apo, resting, and desensitized channels show similar profiles, suggests that rearrangement in the LBD layer upon desensitization is sufficient to allow the desensitized state channel to adopt a nearly identical non-conducting conformation as that present prior to activation.

The desensitized state atomic model allows examination of the question of how the M3-S2 linkers connecting the ion channel and LBD layers mediate the striking differences between resting, pre-activated and desensitized state LBD structures. One aspect of these large changes in structure is that the M3-S2 linkers that couple LBD cleft closure to channel opening must somehow accommodate the height and pitch differences between AC and BD LBDs ([Fig. 2f](#F2){ref-type="fig"}). We first considered differences between AC and BD chains of the TMD, and their connectivity to the LBD layer. Notably, while the two pairs of chains have nearly identical conformations in the TM domain, the linkers adopt different conformations as evidenced by Phi-Psi analysis, and the heights of the structures gradually diverge while still retaining overall \~4-fold in plane rotational symmetry ([Fig. 4a](#F4){ref-type="fig"}). Specifically, beginning at M633 the AC linkers rise at a faster rate than their BD counterparts, with the difference reaching its maximum of \~6 Å at K645 ([Fig. 4a, 4c](#F4){ref-type="fig"}). Thus, it is this height discrepancy that allows for the difference in pitch of the AC versus BD LBDs ([Fig. 2f](#F2){ref-type="fig"}), permitting the E/G helices of the AC LBDs to occupy the elevated and tilted position in the staggered desensitization ring, whereas the compact BD subunit linkers map to the lower height of the BD LBDs. Despite the vertical asymmetry of linkers, their in-plane rotational symmetry is \~4-fold, as evidenced by orientations of helices E, the site at which linkers couple to the LBD. This mirrors the in-plane rotational symmetry of the LBD tetramer ([Fig. 1d](#F1){ref-type="fig"}).

Comparison of differences between the M3-S2 regions of the AC and BD subunit enables identification of the position that serves as the hinge for the transition to the \~4-fold symmetry in the desensitized state ([Fig. 4d](#F4){ref-type="fig"}). As a structural reference for this analysis, we used the antagonist-bound resting state of GluA2^[@R6]^. Chains A and C have similar conformations ([Fig. 4a](#F4){ref-type="fig"}), consistent with the observation of small movements of the corresponding LBDs between resting and desensitized states. Conversely, in the B and D chains, there are 135--180° changes in main chain Psi angles over a 3 residue stretch, from E634-P636 in the GluK2 desensitized state, the trajectory of which deviates significantly from that observed in the GluA2 resting state, indicating that this region serves as a pivot point around which channel closure drives LBD layer rearrangement during desensitization^[@R4]^.

The central new findings of our study are that the GluK2 desensitized state displays 2-fold, quasi 4-fold and 4-fold in-plane rotational symmetries, for the ATD, LBD, and TM regions, respectively. However, surprising mismatches between axial and in-plane symmetry are found embedded in the LBD layer. These features ultimately confer the receptor with overall 2-2-4 symmetry with the LBD layer mediating an elegant structural compromise between the 2-fold symmetric ATD layer, and the 4-fold symmetric ion channel. The 2-fold character of the LBD desensitization ring is defined by the need to accommodate the ATD layer, which effectively "rocks" the AC LBDs backwards away from the central axis. The 4-fold character of the LBD layer arises from the critical need for it to match the symmetry of the ion channel, and thereby allow closing of the ion channel to relieve receptor "tension" driven by LBD closure during activation^[@R3],[@R4],[@R10]^.

The high-resolution desensitized GluK2 structure reported here helps close an important gap in glutamate receptor biology, permitting extensive comparison between high-resolution structures of resting and pre-activated iGluRs, thus providing a more comprehensive picture of the receptor gating cycle. We conclude that the previously undocumented 2-fold symmetric desensitization ring formed by the inner face of the LBD tetramer, combined with ATD-LBD interfaces, and most likely the high stability of the ion channel in its closed conformation, contribute to the deep energy well that the receptor enters from the active state. Furthermore, the staggered helix interactions in the desensitization ring likely serve collectively as a molecular switch that, upon agonist unbinding and opening of the jaws of individual LBDs, is disrupted and triggers destabilization of the desensitized state. This event would thereby permit a structural rearrangement back to the resting state with an intact LBD dimer of dimers assembly, thus completing the gating cycle.

METHODS {#S1}
=======

Protein expression and purification {#S2}
-----------------------------------

The full-length rat GluK2 subunit cDNA sequence (UniProt ID: P42260) was cloned into the pFastBac1 vector for protein expression in insect cells. GluK2~EM~ was created by introducing four mutations in the LBD (A487T, A658S, N690S and F704L) which convert the sequence to that found in GluK1, creating a high affinity binding site for the GluK1 selective antagonist LY466195^[@R16]^. The construct was RNA edited at position 536 (I to V) and had two mutations (C545V (M1) and C564S (M1-M2 loop) which increased yield and tetramer stability. For fluorescence detection and affinity purification, a thrombin recognition site and linker sequence (GLVPRGSAAAA) was inserted between GluK2~EM~ and the coding sequence for the A207K dimerization suppressed EGFP mutant, with a C-terminal SGLRHis8 affinity tag. Membranes isolated from Sf9 cells were solubilized and purified as described previously using n-dodecyl-β-D-maltopyranoside (DDM) and cholesterol hemisuccinate (CHS)^[@R5]^. The GluK2~EM~ S1S2 LBD construct encoding residues S398-K513 and P636-E775 connected by a GT dipeptide linker was expressed in Escherichia coli and purified as reported previously for wild type GluK2^[@R26]^.

Specimen preparation and cryo-electron microscopy {#S3}
-------------------------------------------------

Vitrified samples of GluK2 solublized in DDM-CHS were prepared with protein concentrated to 4.2 mg/mL. A volume of 3 μL was added to R1.2/1.3 holey carbon grids (Quantifoil) rendered hydrophilic with self-assembled monolayer functionalization^[@R27]^, and grids were frozen with a Vitrobot Mk IV robot (FEI Company, Hillsboro, OR, USA) or a Leica EM GP (Leica Microsystems Inc., Buffalo Grove, IL, USA).

Data was collected using a Titan Krios, operated at 300 kV, aligned for parallel illumination, and equipped with a GIF Quantum Energy Filter (Gatan, Inc.) operated in zero-energy-loss mode with a slit width of 20 eV ([Extended Data Table 2](#T2){ref-type="table"}). Images were acquired manually on a K2 Summit camera (Gatan, Inc.), at 105,000 X nominal magnification corresponding to a 1.324 Å physical pixel size. Each exposure was recorded in super-resolution mode as a 38-frame movie, with dose rate and exposure time of 3 e Å^−1^ s^−1^ and 15 s, respectively.

Image processing and structure analysis {#S4}
---------------------------------------

Movie frames from the K2 Summit were aligned using the UCSF drift correction software^[@R28]^. Data was 2 × 2 binned, yielding a pixel size of 1.324 Å. Particles were manually identified and selected using the program e2boxer within the EMAN2 program suite^[@R29]^. Integrated and unintegrated multi-frame images were processed in the framework of either Relion version 1.3 or 1.4^[@R30]^. The integrated images were used for CTF estimation with CTFFIND3^[@R31]^ as implemented in the Relion workflow. Single particles were subjected to 2D (T = 2) and 3D (T = 4) classifications with C2 symmetry imposed (or C1 symmetry where specified) and low-population or poorly-defined classes were discarded at both stages. Data was subjected to particle polishing as implemented in Relion^[@R32]^, and resulting "shiny" particles refined to give final structures that were B-factor corrected in Relion. "Gold standard" FSC resolution plots were calculated using the EMAN2 program e2proc3d^[@R29]^ with a soft shape mask applied to independent unfiltered half maps from Relion. Three-dimensional classification was bootstrapped using previous GluK2 cryo-EM maps filtered to 60 Å as initial models. [Extended Data Table 2](#T2){ref-type="table"} contains numbers of micrographs and particles used at all stages of image processing. Graphics for figures were prepared using UCSF Chimera^[@R33]^ and PyMOL^[@R34]^. The ion channel profiles in [Figs. 3d and 3e](#F3){ref-type="fig"} were determined using the HOLE program^[@R35]^. Local resolution visualizations in [Extended Data Figs. 1e](#F5){ref-type="fig"} and [3e](#F7){ref-type="fig"} were generated using the blocres utility in the Bsoft package^[@R36]^.

LBD crystallization and atomic model building of full-length receptor {#S5}
---------------------------------------------------------------------

Crystals for the GluK2~EM~ LBD complex with (2S,4R)-4-methylglutamate were grown using a reservoir containing 18% PEG 8K, with a buffer solution of 20 mM NaCl, 1 mM EDTA, 5 mM 2S,4R-4-methylglutamate and 2 mM Tris pH 8.0. Crystals for the GluK2~EM~ LBD complex with LY466195 were grown using a reservoir containing 2M Li~2~SO~4~, 3% PEG 4K, 0.1 M MgSO~4~, 5 mM LY466195 and 0.1 M Na Acetate pH 5.5. The structures were solved by molecular replacement, using the upper and lower lobes of the wild type GluK2 LBD (PDB ID: 3G3F) glutamate complex as search probes, and refined to good statistics using PHENIX^[@R37]^ and COOT^[@R38]^ ([Extended Data Table 3](#T3){ref-type="table"}).

The GluK2~EM~ LBD complex with 2S,4R-4-methylglutamate crystallized with one protomer in the asymmetric unit. Due in large part to the N690S and F704L mutations the solvent accessible volume of the ligand binding pocket increased from 270 Å^3^ for wild type GluK2 to 310 Å^3^ for GluK2~EM~, comparable to the value of 305 Å^3^ for GluK1^[@R26]^. Identical to the structure of GluK1 an additional trapped water molecule entered the binding pocket, forming a hydrogen bond network made by the Asn690 side chain carbonyl oxygen atom in the wild type protein. A dimer assembly essentially identical to that for wild type GluK2 (PDB ID: 3G3F) was created by least squares superposition using domain one coordinates (RMSD 0.23 Å) to position two GluK2~EM~ protomers. The GluK2~EM~ LBD complex with LY466195 crystallized as a dimer, but surprisingly one protomer contained a bound glutamate molecule while the second protomer bound LY466195. The glutamate bound protomer adopted a closed cleft conformation, while the LY466196 bound protomer adopted an open cleft conformation produced by a 27° rotation of domain 2. The structure revealed hydrogen bonds with the bound LY466195 ligand formed by the hydroxyl groups of the A487T and A658S mutant side chains, while the N690S mutation relieved a bad steric clash that prevents binding of LY466195 to wild type GluK2. A dimer with two open cleft protomers was created by least squares superposition using domain one coordinates (RMSD 0.31 Å) to position a copy of the LY466195 bound protomer in place of the glutamate bound protomer.

The GluK2~EM~ desensitized state atomic model was built using rigid body fitting in UCSF Chimera^[@R33]^ of two copies of a GluK2 ATD dimer crystal structure (PDB ID: 3H6G) and four copies of a 2S,4R-4-methylglutamate-bound GluK2~EM~ LBD protomer crystal structure (PDB ID: 5CMM) to the cryo-EM density map, followed by rebuilding in COOT. The ion channel and linkers to the LBD were also built in COOT using the GluA2 resting state crystal structure (PDB ID: 3KG2) as a guide, followed by real space refinement of the complete model using PHENIX. The ATD-LBD linker regions spanning residues 385-398 were then modeled using RosettaCM^[@R39]^ with C2 symmetry and the real space refined GluK2~EM~ model as input. The antagonist-bound resting state model of GluK2~EM~ was built from rigid body fits of two copies of a GluK2 ATD dimer crystal structure (PDB ID: 3H6G) and two copies of the manually generated dimer corresponding to the LY466195-bound GluK2~EM~ LBD (PDB ID: 5CMK).

Electrophysiological experiments {#S6}
--------------------------------

Outside-out patch recordings from HEK cells transfected with wild type and mutant GluK2 constructs, with fast solution exchange achieved using four-bore glass tubing mounted on a P245.30 piezoelectric stack driven by a P-270 HVA amplifier (Physik Instrumente), were performed at room temperature using a Axopatch 200A amplifier as described previously^[@R40]^. The external solution contained (in mM) 145 NaCl, 2.5 KCl, 1.8 CaCl~2~, 1 MgCl~2~, 5 HEPES (pH 7.3), and 10 glucose, with 10 mM L-glutamate used for activation. The internal solution contained (in mM) 105 NaCl, 20 NaF, 5 Na~4~BAPTA, 0.5 CaCl~2~, 5 HEPES (pH 7.3), and 10 mM Na~2~ATP. Two electrode voltage clamp recordings at a holding potential of −60 mV, with 3M KCl agarose tipped electrodes of resistance 0.1 -- 0.8 MΩ, were performed using stage 5--6 *Xenopus* oocytes, 2--3 days after injection of cRNA for either GluK2~EM~ or wild type GluK2. The bath solution contained 100 mM NaCl, 1 mM KCl, 5 mM HEPES pH 7.5, 0.8 mM BaCl~2~ and 1 mM MgCl~2~, with concanavalin A (Sigma Type IV) 0.6 mg/ml used to block desensitization. The initial response to 100 μM glutamate following preincubation with 1.5 -- 300 nM LY466195 was recorded as a step response before the slow increase in current due to dissociation of antagonist and fit with the Hill equation.

Extended Data {#S7}
=============

![Desensitized GluK2 imaging and structure determination\
**a, b,** Representative cryo-EM image of GluK2~EM~ solubilized in DDM-CHS and bound by 2S,4R-4-methylglutamate (a), with the corresponding image power spectrum and CTF estimate showing signal beyond 3 Å resolution (b, solid and dotted lines, respectively). The defocus value for the image is 1.5 μm. In panel (a) particles are highlighted with circles, and image binning at 4x and uniform level adjustments were used to make particles apparent. Scale bar is 500 Å. **c,** Subset of selected two-dimensional class averages. **d,** FSC curve with reported resolution of 3.8 Å at the 0.143 crossing. **e,** Structure of agonist bound GluK2~EM~ colored according to local resolution, shown at three progressively increasing contours.](nihms809582f5){#F5}

![Desensitized GluK2 transmembrane and glycosylation features\
**a, b,** Cryo-EM density for resolved S1-M1 (a) and M3-S2 (b) linkers and TM helices, displayed with Cα trace of the atomic model. **c,** Representative sites with densities for complex glycans at Asn244, Asn347, and Asn399.](nihms809582f6){#F6}

![Reconstruction of desensitized GluK2 without computational symmetry\
**a,** Cryo-EM density map for the reconstruction of agonist bound GluK2 without imposition of computational symmetry, and colored according to local resolution. **b,** FSC curve with reported resolution of 4.4 Å at the 0.143 crossing. **c,** Segmentation of individual GluK2 chains of the asymmetric reconstruction. The density map segmentation is shown fitted with a trace representation of the model displayed in [Fig. 1b](#F1){ref-type="fig"}.](nihms809582f7){#F7}

![Inhibition of GluK2~EM~ by LY466195 and LBD crystal structures for agonist and antagonist complexes\
**a,** Crystal structure for the GluK2~EM~ isolated LBD dimer assembly complex with 2S,4R-4-methylglutamate; the upper/lower lobes for the two subunits are colored orange/pale yellow and teal/pale cyan respectively; the dashed line indicates the separation of the lower lobes measured as the distance between the Cα positions of Ile637. **b,** Crystal structure for the GluK2~EM~ isolated LBD dimer assembly complex with LY466195 illustrating the large decrease in separation of the lower lobes compared to the agonist complex. Coloring is the same as in (a). **c,** Responses to 100 μM glutamate recorded under two electrode voltage clamp for GluK2~EM~ (top) and wild type GluK2 (bottom); the initial response to glutamate recorded after prior application of 300 nM LY466195 showed nearly complete block for GluK2~EM~ with no change in amplitude for wild type. **d,** Concentration dependence for inhibition of GluK2~EM~ by LY466195 yielded an IC~50~ of 30 nM.](nihms809582f8){#F8}

![Imaging and structure of GluK2~EM~ bound by antagonist LY466195\
**a, b,** Representative cryo-EM image of GluK2~EM~ solubilized in DDM-CHS and bound by LY466195 (a), with the corresponding image power spectrum and CTF estimate showing signal beyond 6 Å resolution (b, solid and dotted lines, respectively). The defocus value for the image is 2.7 μm. In panel (a) particles are highlighted with circles, and image binning at 4x and uniform level adjustments were used to make particles apparent. Scale bar is 500 Å. **c,** Subset of selected two-dimensional class averages. **d,** Cryo-EM density map for GluA2 bound to ZK200775^[@R4]^ (left), density map for GluK2~EM~ bound to LY466195 (middle) and its corresponding molecular model built from ATD and LBD dimers (right). **e,** FSC curve with reported resolution of 11.6 Å at 0.143 crossing.](nihms809582f9){#F9}

![ATD-LBD interface of desensitized GluK2\
**a,** Desensitized GluK2 shown in surface representation with ATD-LBD interfaces highlighted. **b,** Top down view of LBD layer shown with perspective indicated by eye icon in (a). **c,** Underside of the ATD layer as viewed after peeling away from LBD layer. Dashed lines in (a) highlight where the layers are separated. In all panels, interfaces on chain A and C are in green and blue, respectively. **d,** Table with residues that mediate ATD-LBD interaction. **e, f,** Cartoon representation of LBD and ATD layers from same views as in (b) and (c), with interface residues colored to correspond with table in (d).](nihms809582f10){#F10}

![Desensitization ring residues that influence recovery kinetics\
**a--d,** Rate of recovery from desensitization measured using twin pulse applications of 10 mM glutamate (data points show mean ± SD; fits are shown in red). **a,** Wild type GluK2 fit with a single exponential. **b,** D672R fit with the sum of two exponentials with the response for wild type shown as a black line; **c,** S669R D672R double mutant fit with the sum of two exponentials with the response for wild type shown as a black line. **d,** Time to 50% recovery in seconds. **e--h,** Top views of the GluK2 desensitization ring with residues found to influence recovery kinetics when mutated. Each panel shows the wild-type residue alpha carbon position as a sphere. Positions for the S669R and D672R mutations from the present study are shown in (e) and (f), respectively. The A676T and S679R positions found in previous studies^[@R20],[@R21]^, are in (g) and (h), respectively.](nihms809582f11){#F11}

###### Electrophysiological analysis

For wild type GluK2, the D672R mutant and the S669R/D672R double mutant values (mean ± SEM) are reported for the peak amplitude of the response to 10 mM glutamate (Amp); the percent desensitization measured 50 ms after the start of the application of glutamate; the time constant of onset of desensitization determined using a single exponential fit (Tau des); the amplitude of the fast component of recovery from desensitization (Amp fast); and the rate constants of the fast (k~fast~) and slow (k~slow~) components of recovery from desensitization determined from double exponential fits. Values for S679R are from Carbone and Plested^[@R20]^; values for A676T are from Fleck et al^[@R21]^.

                Amp (nA)             \% Desens     Tau des       Amp fast %   k~fast~ s^−1^   k~slow~ s^−1^
  ------------- -------------------- ------------- ------------- ------------ --------------- ---------------
  WT            1.41 ± 0.27 (n=13)   99.3 ± 0.19   3.56 ± 0.40   100          0.79 ± 0.09     
  D672R         0.56 ± 0.10 (n=12)   99.0 ± 0.21   2.06 ± 0.11   85.3 ± 3.4   2.48 ± 0.27     0.14 ± 0.04
  S669R/D672R   0.21 ± 0.06 (n=10)   99.4 ± 0.17   2.08 ± 0.15   74.8 ± 3.7   3.25 ± 0.31     0.20 ± 0.06
  S679R         NR                   99.5          4.8           100          1.3             
  A676T         NR                   NR            3.0           100          1.4             

###### Cryo-EM data collection and structural analysis

Imaging conditions and data processing. The table shows the robot or robots used to make samples; the number of micrographs used for image processing; the number of particles manually designated in the micrographs; the number of particles retained after 2D classification; the number of particles retained after 3D classification and used for structure refinement; and the resolution and symmetry.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample           Robot(s)         Micrographs   Particles prior to depletion   Particles retained after 2D classification   Particles in 3D reconstruction   Resolution (Å)
  ---------------- ---------------- ------------- ------------------------------ -------------------------------------------- -------------------------------- ---------------------
  GluK2-SYM        Leica EM GP\     2,454         166,311                        166,284                                      62,244 (C2 symmetry)\            3.76 (C2 symmetry)\
                   Vitrobot Mk IV                                                                                             62,552 (C1 symmetry)             4.36 (C1 symmetry)

  GluK2-LY466195   Vitrobot Mk IV   1,774         93,583                         92,945                                       31,000                           11.60 (C2 symmetry)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Crystallographic data collection and refinement statistics

Crystallographic data collection and refinement statistics for LBD structures.

  ------------------------------------------------------------------------ --------------------- ---------------------
  **DATA COLLECTION**                                                      (2S,4R)-4-MethylGlu   LY466195 - Glu
  Space group                                                              P6~1~                 P6~1~22
  *Unit cell a, b, c* (Å)                                                  52.3, 52.3, 170.9     102.8, 102.8, 282.0
  *a, β, g*                                                                90, 90, 120           90, 90, 120
  Number per a.u.                                                          1                     2
  Wavelength (Å)                                                           1.0000                1.0000
  Resolution (Å) [a](#TFN2){ref-type="table-fn"}                           30 -- 1.27 (1.29)     30 -- 1.8 (1.83)
  Unique observations                                                      68757                 82330
  Mean redundancy [b](#TFN3){ref-type="table-fn"}                          7.0 (4.7)             14.5 (14.2)
  Completeness (%) [b](#TFN3){ref-type="table-fn"}                         99.4 (95.2)           100 (100)
  R~merge~[b](#TFN3){ref-type="table-fn"}[c](#TFN4){ref-type="table-fn"}   0.043 (0.335)         0.058 (\> 1)
  R~pim~[b](#TFN3){ref-type="table-fn"}[d](#TFN5){ref-type="table-fn"}     0.017 (0.166)         0.017 (0.326)
  I/s(I)[b](#TFN3){ref-type="table-fn"}                                    45.6 (3.8)            48.4 (2.8)
  **REFINEMENT**                                                                                 
  Resolution (Å)                                                           27.29 -- 1.27         29.86 -- 1.80
  Protein atoms (AC) [e](#TFN6){ref-type="table-fn"}                       2127 (80)             4125 (95)
  Ligand atoms                                                             11                    34
  Li/Cl/SO~4~ ions                                                         -/-/-                 2/10/2
  Water atoms                                                              410                   533
  R~work~/R~free~ (%) [f](#TFN7){ref-type="table-fn"}                      14.3/16.3             16.4/18.7
  *rms deviations*                                                                               
  Bond lengths (Å)                                                         0.009                 0.014
  Bond angles °                                                            1.24                  1.40
  *Mean B-Values (Å^2^)*                                                                         
  Protein overall                                                          20.9                  27.5
  MC/SC [g](#TFN8){ref-type="table-fn"}                                    18.6/23.2             23.4/31.7
  Ligand                                                                   13.2                  19.8
  Li/Cl/SO~4~ ions                                                         -/-/-                 23.8/57.1/34.8
  Water                                                                    34.9                  34.1
  *Ramachandran* % [h](#TFN9){ref-type="table-fn"}                         97.8/0                97.9/0
  ------------------------------------------------------------------------ --------------------- ---------------------

Superscripts a--h denote the following:

Values in parenthesis indicate the low resolution limit for the highest-resolution shell of data.

Values in parenthesis indicate statistics for the highest-resolution shell of data.

R~merge~ = (Σ\|I*~I~* − \<I*~I~*\>\|)/Σ*~I~* \|I*~I~*\|, where \<I*~I~*\> is the mean I*~I~* over symmetry--equivalent reflections.

$R_{\text{pim}} = (\sqrt{1/(n - 1)}\sum_{I = 1}^{n}II_{I}\, I)/\sum_{I}I_{I}$, where \<I*~I~*\> is the mean I*~I~* over symmetry--equivalent reflections.

Alternate conformations.

R~work~ = (Σ \|\|**F**~o~\| − \|**F**~c~\|\|)/Σ \|**F**~o~\|, where **F**~o~ and **F**~c~ denote observed and calculated structure factors, respectively; 5% of the reflections were set aside for the calculation of the R~free~ value.

Main chain/Side chain.

Preferred/Disallowed conformations.
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![Desensitized kainate receptor at 3.8 Å resolution\
**a, b,** Cryo-EM density map (a) and atomic model (b) of 2S,4R-4-methylglutamate bound GluK2~EM~ with each chain colored uniquely. Panel (a) has features shown from two map contours. **c,** Side and top view of the ATD tetramer, with cartoon highlighting 2-fold symmetry in the ATD layer. **d,** Top view of LBD tetramer with cartoon illustrating apparent 4-fold symmetry of the LBD layer when seen down the receptor central axis. **e,** Top view of the TMD with cartoon indicating domain symmetry.](nihms809582f1){#F1}

![Desensitization ring\
**a,** Top view of LBD layer highlighting desensitization ring helices E and G colored magenta for AC subunits and cyan for BD subunits. Residues S669 and D672, mutated in functional experiments (g--i), are shown as sticks to highlight their positions. **b,** Edge-on view of desensitization ring interface with perspective indicated by eye icon in (a). **c,** Same perspective as in (b) but rotated 90° to show the second type of E/G interface observed in the desensitization ring. **d,** Illustration of hypothetical desensitization ring arrangement that would yield complete 4-fold symmetry in the LBD layer. The G helices are shown on top layer, and E helices on bottom layer. **e,** Illustration of the experimentally observed desensitization ring arrangement which is staggered and has 2-fold symmetry. **f,** The BD LBDs (left) are less inclined than the AC LBDs (right). This tilting of the AC domains elevates their E/G helices to adopt the upper position in the staggered configuration. Helix B of each LBD is highlighted in yellow as a reference to show domain tilt. **g,** Response to 10 mM glutamate for the D672R mutant, with the onset of desensitization fit by a single exponential of time constant 1.5 ms (red line). The upper trace shows the open tip junction current recorded at the end of the experiment. **h,** Recovery from desensitization, recorded from the same patch, for twin pulse applications of glutamate. The upper trace shows the command to the piezo stack. **i,** Recovery from desensitization for the D672R mutant (data points show mean ± SD, n=12) and wild type GluK2 (dashed line) fit with exponential functions.](nihms809582f2){#F2}

![Desensitized state ion channel\
**a--c,** Selected sidechain densities with atomic model for M1 (a), M3 (b), and M4 (c) helices. **d,** The ion channel with surface modeling of the channel. Regions with pore radius less than 1.15 Å are red, water accessible parts with radius between 1.15 Å and 2.30 Å are green, and wide areas with pore radius greater than 2.30 Å are blue. **e,** Plot of pore radius as a function of channel position with desensitized GluK2 (black), apo GluA2 (blue, PDB ID: 4U2P), antagonist-bound resting GluA2 (orange, PDB ID: 3KG2), and pre-activated GluA2 (magenta, PDB ID: 4U5B). Residue labels on right hand Y-axis mark the position of the respective channel forming side chains.](nihms809582f3){#F3}

![LBD-TM linkers mediate channel closing and LBD reorganization\
**a,** Comparison of the regions encompassing the M3, M3-S2 linkers, and E helices for AC (magenta) and BD (cyan) chains of desensitized state GluK2~EM~. **b,** The vertical rise in Cα position as a function of residue number for chains AC (magenta) versus BD (cyan). **c,** Measurement of how Cα positions on desensitized state GluK2 chains A, C, B, and D deviate from corresponding positions on resting state GluA2~cryst~ which was used as a reference. Line coloring is the same as in panel (b). Dotted lines indicate AB chains, with solid lines for CD chains. The magenta traces show low deviation, reflecting the similarity between these regions of the AC subunits of desensitized GluK2 and the resting state GluA2 structure used as a reference (PDB ID: 3KG2). The cyan trace begins to deviate significantly at the circular markers corresponding to R632 (R628) GluK2 (GluA2). This reflects the dramatic difference in BD linker arrangements between the resting and desensitized states. **d,** The desensitized GluK2 channel with the region considered in (c). M3 helices and M3-S2 linkers are colored as in other panels, with pre-M1, M1 and M4 regions colored in yellow. Spheres mark residue R632 on all four TM chains. **e,** Schematic view of structural rearrangements that are involved in transition from resting to activated to desensitized states of glutamate receptors. [Supplementary Video 1](#SD2){ref-type="supplementary-material"} shows an animation of the gating cycle.](nihms809582f4){#F4}
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